
    
      Study ANK-700-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of
      ANK-700 in patients with relapsing remitting multiple sclerosis (rrms).

      An overview of the two parts and proposed dose groups is given below:

      Part A (SAD): Patients will receive a single dose of ANK-700. Part B (MAD): Patients will
      receive three doses of either ANK-700 or placebo.
    
  